Antioxidized LDL antibodies are associated with different metabolic pathways in patients with atherosclerotic plaque and type 2 diabetes

Diabetes Care

Volumn 36, Issue 4, 2013, Pages 1006-1011

  Bernal Lopez, M Rosa ^a,b   Garrido Sanchez, Lourdes ^c,d   Gomez Carrillo, Victor ^e   Gallego Perales, Jose Luis ^e   Llorente Cortes, Vicenta ^f   Calleja, Fernando ^e   Gomez Huelgas, Ricardo ^b,e   Badimon, Lina ^b,f   Tinahones, Francisco J ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GELATINASE A; GLICLAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INSULIN; METFORMIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BAX; REPAGLINIDE; STROMELYSIN 2; TISSUE FACTOR PATHWAY INHIBITOR; VASCULOTROPIN A;

ADULT; AGED; AKT1 GENE; APOPTOSIS; ARTERY OCCLUSION; ARTICLE; ATHEROSCLEROTIC PLAQUE; BAX GENE; BLOOD VESSEL BIOPSY; CASPASE 3 GENE; CDKN1A GENE; CELL CYCLE ARREST; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; FEMORAL VEIN; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; LEG AMPUTATION; LIPID METABOLISM; MALE; METABOLISM; MMP10 GENE; MMP2 GENE; NF KAPPA B GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE SEQUENCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; PPARG GENE; SCARB1 GENE; TFPI GENE; VEGFA GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; DIABETES MELLITUS, TYPE 2; FEMALE; FEMORAL VEIN; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOPROTEINS, LDL; MALE; METABOLIC NETWORKS AND PATHWAYS; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; POPLITEAL ARTERY; REAL-TIME POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84875469057     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1030     Document Type: Article

References (33)

1. Gaziano JM. Dietary antioxidants and cardiovascular disease. Vitam Horm 2000;58: 299-320
2. Catapano AL, Maggi FM, Tragni E. Low density lipoprotein oxidation, antioxidants, and atherosclerosis. Curr Opin Cardiol 2000;15:355-363
3. Palinski W, Rosenfeld ME, Ylä-Herttuala S, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A 1989;86:1372-1376
4. Inoue T, Uchida T, Kamishirado H, Takayanagi K, Hayashi T, Morooka S. Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease. J Am Coll Cardiol 2001;37:775-779
5. Che J, Li G, Wang W, et al. Serum autoantibodies against human oxidized lowdensity lipoproteins are inversely associated with severity of coronary stenotic lesions calculated by Gensini score. Cardiol J 2011; 18:364-370
6. Wang JJ, Han AZ, Meng Y, et al. Measurement of oxidized lipoprotein (a) in patients with acute coronary syndromes and stable coronary artery disease by 2 ELISAs: using different capture antibody against oxidized lipoprotein (a) or oxidized LDL. Clin Biochem 2010;43:571-575
7. Medeiros AM, von Mühlen CA, Gidlund MA, Bodanese R, Gottlieb MG, Bodanese LC. Antibodies against oxLDL and acute coronary syndrome. Arq Bras Cardiol 2010;95:47-54
8. Monaco C, Crea F, Niccoli G, et al. Autoantibodies against oxidized low density lipoproteins in patients with stable angina, unstable angina or peripheral vascular disease; pathophysiological implications. Eur Heart J 2001;22:1572-1577
9. Tinahones FJ, Gómez-Zumaquero JM, Rojo-Martínez G, et al. Increased levels of anti-oxidized low-density lipoprotein antibodies are associated with reduced levels of cholesterol in the general population. Metabolism 2002;51:429-431
10. Garrido-Sánchez L, García-Fuentes E, Cardona F, Rojo-Martínez G, Soriguer F, Tinahones FJ. Anti-oxidized LDL antibody levels are reduced in women with hypertension. Eur J Clin Invest 2009;39: 800-806
11. Garrido-Sánchez L, García-Almeida JM, García-Serrano S, et al. Improved carbohydrate metabolism after bariatric surgery raises antioxidized LDL antibody levels in morbidly obese patients. Diabetes Care 2008;31:2258-2264
12. Hulthe J, Wikstrand J, Lidell A, Wendelhag I, Hansson GK, Wiklund O. Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1998;18: 1203-1211
13. Festa A, Kopp HP, Schernthaner G, Menzel EJ. Autoantibodies to oxidised low density lipoproteins in IDDM are inversely related to metabolic control and microvascular complications. Diabetologia 1998;41:350-356
14. Craig WY, Poulin SE, Neveux LM, et al. Anti-oxidized LDL antibodies and antiphospholipid antibodies in healthy subjects: relationship with lipoprotein-and oxidation-related analytes. J Autoimmun 1995;8:713-726
15. Tinahones FJ, Gómez-Zumaquero JM, Garrido-Sánchez L, et al. Influence of age and sex on levels of anti-oxidized LDL antibodies and anti-LDL immune complexes in the general population. J Lipid Res 2005;46:452-457
16. Patel RS, Al Mheid I, Morris AA, et al. Oxidative stress is associated with impaired arterial elasticity. Atherosclerosis 2011;218:90-95
17. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011;473:317-325
18. Martinet W, Schrijvers DM, DeMeyer GR. Necrotic cell death in atherosclerosis. Basic Res Cardiol 2011;106:749-760
19. Rodríguez I, Coto E, Reguero JR, et al. Role of the CDKN1A/p21, CDKN1C/p57, and CDKN2A/p16 genes in the risk of atherosclerosis and myocardial infarction. Cell Cycle 2007;6:620-625
20. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006;86:515-581
21. Karvonen J, Päivänsalo M, Kesäniemi YA, Hörkkö S. Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation 2003;108:2107-2112
22. Lewis MJ, Malik TH, Ehrenstein MR, Boyle JJ, Botto M, Haskard DO. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2009;120:417-426
23. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001;7:425-429
24. Bernal-Lopez MR, Llorente-Cortes V, Calleja F, et al. Effect of different degrees of impaired glucose metabolism on the expression of inflammatory markers in monocytes of patients with atherosclerosis. Acta Diabetol 14 October 2011 [Epub ahead of print]]
25. Lenglet S, Thomas A, Chaurand P, Galan K, Mach F, Montecucco F. Molecular imaging of matrix metalloproteinases in atherosclerotic plaques. Thromb Haemost 2012;107:409-416
26. Orbe J, Rodríguez JA, Calvayrac O, et al. Matrix metalloproteinase-10 is upregulated by thrombin in endothelial cells and increased in patients with enhanced thrombin generation. Arterioscler Thromb Vasc Biol 2009;29:2109-2116
27. Vergeer M, Korporaal SJA, Franssen R, et al. Genetic variant of the scavenger receptor BI in humans. N Engl J Med 2011; 364:136-145
28. Sugawara A, Uruno A, Matsuda K, Funato T, Saito-Hakoda A, Kudo M, Ito S. Effects of PPARg agonists against vascular and renal dysfunction. Curr Mol Pharmacol. 2012;5:2458-254
29. Genolet R, Wahli W, Michalik L. PPARs as drug targets to modulate inflammatory responses? Curr Drug Targets Inflamm Allergy 2004;3:361-375
30. Mitra S, Khaidakov M, Lu J, et al. Prior exposure to oxidized low-density lipoprotein limits apoptosis in subsequent generations of endothelial cells by altering promoter methylation. Am J PhysiolHeart Circ Physiol 2011;301:H506-H513
31. Al-Khalaf HH, Hendrayani SF, Aboussekhra A. ATR controls the p21(WAF1/Cip1) protein up-regulation and apoptosis in response to low UV fluences. Mol Carcinog 2012;51:930-938
32. Tokumoto M, Tsuruya K, Fukuda K, et al. Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor and cyclin-dependent kinase inhibitors, p21 and p27. Nephrol Dial Transplant 2003;18(Suppl. 3):iii9-iii122
33. el-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54: 1169-1174